Advanced search
Publication Cover
Pharmaceutical Biology Volume 57, 2019 - Issue 1
Submit an article Journal homepage
2,695
Views
30
CrossRef citations to date
0
Altmetric
Research Article

Astragaloside IV alleviates heart failure by promoting angiogenesis through the JAK-STAT3 pathway

Yan-Bo SuiFirst Unit of Department of Cardiology, First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China;
,
Yu WangHeilongjiang University of Chinese Medicine, Harbin, China;
,
Li LiuFirst Unit of Department of Cardiology, First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China; Correspondence[email protected]
,
Feng LiuThird Unit of Department of Cardiology, First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China; Correspondence[email protected]
&
Yi-Qing ZhangFourth Unit of Department of Cardiology, First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, ChinaCorrespondence[email protected]
Pages 48-54 | Received 24 Jul 2018, Accepted 19 Dec 2018, Published online: 24 Mar 2019

References

  • Bui AL, Horwich TB, Fonarow GC. 2011. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 8:30–41.
  • Carmeliet P. 2005. Angiogenesis in life, disease and medicine. Nature. 438:932–936.
  • Chantal L, Wickwar VB, Wlodek K. 1998. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation. 97:645–650.
  • Cohn JN, Cohn JN, Cohn JN. 1996. Drug therapy – The management of chronic heart failure. New Engl J Med. 335:490–498.
  • Dong Z, Zhao P, Xu M, Zhang C, Guo W, Chen H, Tian J, Wei H, Lu R, Cao T. 2017. Astragaloside IV alleviates heart failure via activating PPARα to switch glycolysis to fatty acid β-oxidation. Sci Rep. 7:2691–269115.
  • Fan D, Takawale A, Shen M, Wang W, Wang X, Basu R, Oudit G, Kassiri Z. 2015. Cardiomyocyte a disintegrin and metalloproteinase 17 (ADAM17) is essential in post-myocardial infarction repair by regulating angiogenesis. Circ Heart Fail. 8:970–979.
  • Ferrara N, Gerber HP, Lecouter J. 2003. The biology of VEGF and its receptors. Nat Med. 9:669–676.
  • Fletcher PJ, Pfeffer JM, Pfeffer MA, Braunwald E. 1981. Left ventricular diastolic pressure-volume relations in rats with healed myocardial infarction. Effects on systolic function. Circ Res. 49:618–626.
  • Hilfiker-Kleiner D, Hilfiker A, Fuchs M, Kaminski K, Schaefer A, Schieffer B, Hillmer A, Schmiedl A, Ding Z, Podewski E, et al. 2004. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res. 95:187–195.
  • Jessup M, Brozena S. 2003. Heart failure. New Engl J Med. 348:2007–2018.
  • Levy DE, Darnell JE. 2002. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 3:651.
  • Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, Ashare AB, Lathi K, Isner JM. 1998. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation. 98:2800–2804.
  • Miller AL. 1998. Botanical influences on cardiovascular disease. Altern Med Rev. 3:422–431.
  • Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. 2006. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 7:359–371.
  • Omura T, Yoshiyama M, Ishikura F, Kobayashi H, Takeuchi K, Beppu S, Yoshikawa J. 2001. Myocardial ischemia activates the JAK-STAT pathway through angiotensin II signaling in in vivo myocardium of rats. J Mol Cell Cardiol. 33:307–316.
  • Osugi T, Oshima Y, Fujio Y, Funamoto M, Yamashita A, Negoro S, Kunisada K, Izumi M, Nakaoka Y, Hirota H, et al. 2002. Cardiac-specific activation of signal transducer and activator of transcription 3 promotes vascular formation in the heart. J Biol Chem. 277:6676.
  • Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. 1985. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation. 72:406–412.
  • Sinclair S. 1998. Chinese herbs: a clinical review of Astragalus, Ligusticum, and Schizandrae. Altern Med Rev. 3:338–344.
  • van der Laan AM, Piek JJ, van Royen N. 2009. Targeting angiogenesis to restore the microcirculation after reperfused MI. Nat Rev Cardiol. 6:515–523.
  • Wang C, Li Y, Yang X, Bi S, Zhang Y, Han D, Zhang D. 2017. Tetramethylpyrazine and astragaloside IV synergistically ameliorate left ventricular remodeling and preserve cardiac function in a rat myocardial infarction model. J Cardiovasc Pharmacol. 69:34–40.
  • Wang SG, Xu Y, Chen JD, Yang CH, Chen XH. 2013. Astragaloside IV stimulates angiogenesis and increases nitric oxide accumulation via JAK2/STAT3 and ERK1/2 pathway. Molecules (Basel, Switzerland). 18:12809–12819.
  • Wang WT, Zhao ZY, Han YM, Wei-Ren XU, Tang LD. 2010. Effects of Astragaloside IV derivative on heart failure in rats. Chin Herb Med. 2:48–53.
  • Ylä-Herttuala S, Alitalo K. 2003. Gene transfer as a tool to induce therapeutic vascular growth. Nat Med. 9:694–701.
  • Yuan GP. 2003. Evaluation of efficacy of astragalus injection in treatment of patients with chronic heart failure. Chin J Clin Pharmacol Ther. 8:710–711.
  • Zhang L, Liu Q, Lu L, Zhao X, Gao X, Wang Y. 2011. Astragaloside IV stimulates angiogenesis and increases hypoxia-inducible factor-1α accumulation via phosphatidylinositol 3-kinase/Akt pathway. J Pharmacol Exp Ther. 338:485–491.
  • Zhao Z, Wang W, Wang F, Zhao K, Han Y, Xu W, Tang L. 2009. Effects of Astragaloside IV on heart failure in rats. Chin Med. 4:6.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.